Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.00% | 11.95% | 31.70% | -48.73% | -56.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.74% | 58.00% | 13.54% | -31.56% | -57.42% |
| Operating Income | -10.74% | -58.00% | -13.54% | 31.56% | 57.42% |
| Income Before Tax | -13.46% | -62.57% | -15.22% | 32.21% | 81.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.46% | -62.57% | -15.22% | 32.21% | 81.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.46% | -62.57% | -15.22% | 32.21% | 81.52% |
| EBIT | -10.74% | -58.00% | -13.54% | 31.56% | 57.42% |
| EBITDA | -10.74% | -58.00% | -22.43% | 28.12% | 55.93% |
| EPS Basic | 54.47% | 33.00% | 47.98% | 68.71% | 89.20% |
| Normalized Basic EPS | 54.47% | 33.00% | 47.98% | 68.71% | 75.53% |
| EPS Diluted | 54.47% | 33.00% | 47.98% | 68.71% | 89.20% |
| Normalized Diluted EPS | 54.47% | 33.00% | 47.98% | 68.71% | 75.53% |
| Average Basic Shares Outstanding | 149.20% | 142.63% | 121.51% | 116.63% | 71.09% |
| Average Diluted Shares Outstanding | 149.20% | 142.63% | 121.51% | 116.63% | 71.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |